Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2016

01-09-2016 | Mini Review

The impact of glycemic variability on diabetic peripheral neuropathy

Authors: Heung Yong Jin, Kyung Ae Lee, Tae Sun Park

Published in: Endocrine | Issue 3/2016

Login to get access

Abstract

Mean glucose values alone cannot explain the patterns of morbidity and mortality due to dysglycemia in diabetes. Development of continuous glucose monitoring systems has improved the analysis and interpretation of glycemic variability. The roles of glycemic components other than constant hyperglycemia in diabetic complications must be investigated because large clinical studies have indicated that risk factors besides the average glucose value of HbA1c are involved in chronic macrocomplications/microcomplications of diabetes. Among these complications, the pathogenesis of diabetic peripheral neuropathy is particularly complex, and several factors related to glucose and nonglucose pathways have been suggested as risk factors. There is little information regarding the effect of glycemic variability on diabetic peripheral neuropathy, unlike other microvascular complications of retinopathy and nephropathy, and whether glycemic variability causes harmful effects is still a matter of debate. In this review, we discuss the relationships between glycemic variability and diabetic peripheral neuropathy, focusing on somatosensory peripheral neuropathies rather than autonomic neuropathies.
Literature
1.
W. Clarke, B. Kovatchev, Statistical tools to analyze continuous glucose monitor data. Diabetes Technol. Ther. 11(Suppl 1) S45–S54 (2009)PubMed
2.
H.S. Jung, Clinical implications of glucose variability: chronic complications of diabetes. Endocrinol. Metab. (Seoul) 30(2), 167–174 (2015)CrossRef
3.
J. Schlichtkrull, O. Munck, M. Jersild, M-value, an index for blood sugar control in diabetics. Ugeskr. Laeger. 126, 815–820 (1964)PubMed
4.
F.J. Service, G.D. Molnar, J.W. Rosevear, E. Ackerman, L.C. Gatewood, W.F. Taylor, Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19(9), 644–655 (1970)CrossRefPubMed
5.
K.D. Kohnert, P. Heinke, L. Vogt, E. Salzsieder, Utility of different glycemic control metrics for optimizing management of diabetes. World J. Diabetes 6(1), 17–29 (2015)CrossRefPubMedPubMedCentral
6.
7.
S. Yagihashi, H. Mizukami, K. Sugimoto, Mechanism of diabetic neuropathy: where are we now and where to go?. J. Diabetes Investig. 2(1), 18–32 (2011)CrossRefPubMed
8.
F. Garcia Soriano, L. Virag, P. Jagtap, E. Szabo, J.G. Mabley, L. Liaudet, A. Marton, D.G. Hoyt, K.G. Murthy, A.L. Salzman, G.J. Southan, C. Szabo, Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med. 7(1), 108–113 (2001)CrossRefPubMed
9.
R.J. Heine, B. Balkau, A. Ceriello, S. Del Prato, E.S. Horton, M.R. Taskinen, What does postprandial hyperglycaemia mean?. Diabet. Med. 21(3), 208–213 (2004)CrossRefPubMed
10.
A.E. Caballero, S. Arora, R. Saouaf, S.C. Lim, P. Smakowski, J.Y. Park, G.L. King, F.W. LoGerfo, E.S. Horton, A. Veves, Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48(9), 1856–1862 (1999)CrossRefPubMed
11.
S. Thrainsdottir, R.A. Malik, L.B. Dahlin, P. Wiksell, K.F. Eriksson, I. Rosen, J. Petersson, D.A. Greene, G. Sundkvist, Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. Diabetes 52(10), 2615–2622 (2003)CrossRefPubMed
12.
R. Stavniichuk, V.R. Drel, H. Shevalye, I. Vareniuk, M.J. Stevens, J.L. Nadler, I.G. Obrosova, Role of 12/15-lipoxygenase in nitrosative stress and peripheral prediabetic and diabetic neuropathies. Free Radic. Biol. Med. 49(6), 1036–1045 (2010)CrossRefPubMedPubMedCentral
13.
S. Tesfaye, N. Chaturvedi, S.E. Eaton, J.D. Ward, C. Manes, C. Ionescu-Tirgoviste, D.R. Witte, J.H. Fuller, E.P.C.S. Group, Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 352(4), 341–350 (2005)CrossRefPubMed
14.
R.M. Herman, J.B. Brower, D.G. Stoddard, A.R. Casano, J.H. Targovnik, J.H. Herman, P. Tearse, Prevalence of somatic small fiber neuropathy in obesity. Int. J. Obes. (Lond) 31(2), 226–235 (2007)CrossRef
15.
16.
L. Quagliaro, L. Piconi, R. Assaloni, L. Martinelli, E. Motz, A. Ceriello, Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52(11), 2795–2804 (2003)CrossRefPubMed
17.
M.J. Kim, H.S. Jung, Y. Hwang-Bo, S.W. Cho, H.C. Jang, S.Y. Kim, K.S. Park, Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta. Diabetol. 50(4), 505–510 (2013)CrossRefPubMed
18.
A. Ceriello, K. Esposito, L. Piconi, M.A. Ihnat, J.E. Thorpe, R. Testa, M. Boemi, D. Giugliano, Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57(5), 1349–1354 (2008)CrossRefPubMed
19.
L. Monnier, C. Colette, D.R. Owens, Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab. Res. Rev. 25(5), 393–402 (2009)CrossRefPubMed
20.
E.S. Kilpatrick, A.S. Rigby, S.L. Atkin, For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet. Med. 27(8), 868–871 (2010)CrossRefPubMed
21.
L. Quagliaro, L. Piconi, R. Assaloni, R. Da Ros, A. Maier, G. Zuodar, A. Ceriello, Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 183(2), 259–267 (2005)CrossRefPubMed
22.
S. Kalopita, S. Liatis, P. Thomakos, I. Vlahodimitris, C. Stathi, N. Katsilambros, N. Tentolouris, K. Makrilakis, Relationship between autonomic nervous system function and continuous interstitial glucose measurement in patients with type 2 diabetes. J. Diabetes Res. 2014, 835392 (2014)CrossRefPubMedPubMedCentral
23.
J.E. Jun, S.M. Jin, J. Baek, S. Oh, K.Y. Hur, M.S. Lee, M.K. Lee, J.H. Kim, The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes. Cardiovasc. Diabetol. 14, 70 (2015)CrossRefPubMedPubMedCentral
24.
25.
S.E. Siegelaar, E.S. Kilpatrick, A.S. Rigby, S.L. Atkin, J.B. Hoekstra, J.H. Devries, Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52(10), 2229–2232 (2009)CrossRefPubMedPubMedCentral
26.
J. Bragd, U. Adamson, L.B. Backlund, P.E. Lins, E. Moberg, P. Oskarsson, Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?. Diabetes Metab. 34(6 Pt 1), 612–616 (2008)CrossRefPubMed
27.
J. Soupal, J. Skrha Jr. M. Fajmon, E. Horova, M. Mraz, J. Skrha, M. Prazny, Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol. Ther. 16(4), 198–203 (2014)CrossRefPubMed
28.
F. Xu, L.H. Zhao, J.B. Su, T. Chen, X.Q. Wang, J.F. Chen, G. Wu, Y. Jin, X.H. Wang, The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab. Syndr. 6(1), 139 (2014)CrossRefPubMedPubMedCentral
29.
S.O. Oyibo, Y.D. Prasad, N.J. Jackson, E.B. Jude, A.J. Boulton, The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet. Med. 19(10), 870–873 (2002)CrossRefPubMed
30.
S. Tesfaye, A.J. Boulton, P.J. Dyck, R. Freeman, M. Horowitz, P. Kempler, G. Lauria, R.A. Malik, V. Spallone, A. Vinik, L. Bernardi, P. Valensi, Toronto Diabetic Neuropathy Expert, G.: diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33(10), 2285–2293 (2010)CrossRefPubMedPubMedCentral
31.
X. Meng, C. Gong, B. Cao, X. Peng, D. Wu, Y. Gu, L. Wei, X. Liang, M. Liu, W. Li, C. Su, Glucose fluctuations in association with oxidative stress among children with T1DM: comparison of different phases. J. Clin. Endocrinol. Metab. 100(5), 1828–1836 (2015)CrossRefPubMed
32.
K. Esposito, F. Nappo, R. Marfella, G. Giugliano, F. Giugliano, M. Ciotola, L. Quagliaro, A. Ceriello, D. Giugliano, Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106(16), 2067–2072 (2002)CrossRefPubMed
33.
K.D. Kohnert, P. Augstein, P. Heinke, E. Zander, K. Peterson, E.J. Freyse, E. Salzsieder, Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res. Clin. Pract. 77(3), 420–426 (2007)CrossRefPubMed
34.
N. Colomo, M.J. Tapia, M.R. Vallejo, F. Garcia-Torres, E. Rubio-Martin, F.F. Caballero, J.M. Jimenez, M.J. Pelaez, A.M. Gomez, I. Sanchez, J.P. Lopez-Siguero, F. Soriguer, M.S. Ruiz de Adana, Glycemic variability and oxidative stress in children, with type 1 diabetes attending a summer camp. An Pediatr (Barc) 81(3), 174–180 (2014)CrossRef
35.
E.S. Kilpatrick, A.S. Rigby, S.L. Atkin, A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 31(11), 2198–2202 (2008)CrossRefPubMedPubMedCentral
36.
Y. Kitahara, K. Miura, K. Takesue, T. Mine, R. Wada, Y. Uchida, S. Ito, S. Yagihashi, Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes. Metabolism 51(11), 1452–1457 (2002)CrossRefPubMed
37.
R.J. Strilka, M.C. Stull, M.S. Clemens, S.C. McCaver, S.B. Armen, Simulation and qualitative analysis of glucose variability, mean glucose, and hypoglycemia after subcutaneous insulin therapy for stress hyperglycemia. Theor. Biol. Med. Model 13, 3 (2016)CrossRefPubMedPubMedCentral
38.
M. Kuroda, T. Shinke, K. Sakaguchi, H. Otake, T. Takaya, Y. Hirota, D. Sugiyama, M. Nakagawa, H. Hariki, T. Inoue, T. Osue, Y. Taniguchi, M. Iwasaki, R. Nishio, H. Kinutani, A. Konishi, N. Hiranuma, H. Takahashi, D. Terashita, K. Hirata, Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy: a prospective observational study. JACC Cardiovasc. Interv. 8(6), 800–811 (2015)CrossRefPubMed
39.
D.J. Zdarska, M. Kvapil, Z. Rusavy, M. Krcma, J. Broz, B. Krivska, P. Kadlecova, Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study. Wien. Klin. Wochenschr. 126(7-8), 228–237 (2014)CrossRefPubMed
40.
S.E. Olsen, M.R. Bjorgaas, B.O. Asvold, T. Sand, M. Stjern, B.M. Frier, K.B. Nilsen, Impaired awareness of hypoglycemia in adults with type 1 diabetes is not associated with autonomic dysfunction or peripheral neuropathy. Diabetes Care 39(3), 426–433 (2016)CrossRefPubMed
Metadata
Title
The impact of glycemic variability on diabetic peripheral neuropathy
Authors
Heung Yong Jin
Kyung Ae Lee
Tae Sun Park
Publication date
01-09-2016
Publisher
Springer US
Published in
Endocrine / Issue 3/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1005-7

Other articles of this Issue 3/2016

Endocrine 3/2016 Go to the issue

Endocrine Methods and Techniques

A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer

Original Article

Clinical and molecular manifestation of fifteen 17OHD patients: a novel mutation and a founder effect

Letter to the Editor

Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH)

Meta-Analysis

Risk factors of gestational diabetes mellitus recurrence: a meta-analysis

Meta-Analysis

Diagnostic accuracy of ultrasound-guided fine needle aspiration biopsy for thyroid malignancy: systematic review and meta-analysis

Research Letter

Epicardial fat is a negative predictor of spine volumetric bone mineral density and trabecular bone score in acromegaly
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits